Allogene Therapeutics Financial Overview
Allogene Therapeutics's market cap is currently $314.62M. The company's EPS TTM is $-0.19; its P/E ratio is -1.41; Allogene Therapeutics is scheduled to report earnings on November 6, 2025, and the estimated EPS forecast is $-0.22. See an overview of income statement, balance sheet, and cash flow financials.
